Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 497-499

  Steele, J P C ^b   O'Doherty, C A ^c   Shamash, J ^c   Evans, M T ^c   Gower, N H ^a   Tischkowitz, M D ^c   Rudd, R M ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Liposomal daunorubicin; Malignant pleural mesothelioma; Phase II trial

Indexed keywords

DAUNORUBICIN; LIPOSOME;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG INDICATION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; MALE; MALIGNANT MESOTHELIOMA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE;

EID: 0034996999     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011139918558     Document Type: Article

References (8)

1. Peto J, Hodgson JT, Matthews FE et al. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-9.
2. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.
3. Baas P, Schouwink H, Zoetmulder FAN. Malignant pleural mesothelioma. Ann Oncol 1998; 9: 139-49.
4. Ong ST, Vogelzang NJ. Chemotherapy in malignant mesothelioma: A review. J Clin Oncol 1996; 14: 1007-17.
5. Forssen EA, Coulter DM, Profitt RT. Selective in vivo localisation of daunorubicin small unilamellar vesicles in solid tumours. Cancer Res 1992; 52: 3255-61.
6. Guaglianone P, Chan K, DelaFlor-Weiss E et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994; 12: 103-10.
7. Gill PS, Espina BM, Muggia F et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996-1003.
8. Richardson DS, Kelsey SM, Johnson SA et al. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 1997; 15: 247-53.